Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Cushing’s Syndrome Patients Show Progress in Corlux Study

By Drug Discovery Trends Editor | June 9, 2011

Corcept Therapeutics Incorporated announced data from a Phase 3 study, which demonstrated that refractory Cushing’s syndrome patients receiving Corlux (mifepristone) experienced significant clinical and metabolic improvements over baseline measurements.

Corlux, a glucocorticoid receptor type II (GR-II) antagonist, has been granted Orphan Drug Designation for the treatment of endogenous Cushing’s syndrome by the U.S. Food and Drug Administration (FDA).

Fifty patients were enrolled in the study;  43 had Cushing’s disease (pituitary tumor), with 42 having prior surgery.

Four patients had ectopic ACTH-producing tumors and three had adrenal cancer.  Forty-six of the patients completed at least 30 days of treatment and were included in the modified intent to treat group (mITT) for the efficacy analysis. Thirty-four patients completed the study.

There were 29 patients enrolled in the glucose intolerant group, and there was a continued improvement in glucose tolerance measured at each of the evaluations.  Of the 12 patients taking insulin at baseline, seven cut their daily dose by at least 50%. 

There were 21 patients enrolled in the hypertension group, of which 38% achieved a 5 mm or greater reduction in diastolic blood pressure without increasing the patient’s prescribed hypertensive medication.  There were a total of 40 patients in the study with a diagnosis of hypertension, among them 17 had a decrease in diastolic blood pressure, and 21 patients had either decrease in diastolic blood pressure or a reduction in medications.

The data demonstrated that refractory Cushing’s Syndrome patients receiving Corlux experienced significant clinical and metabolic improvements over baseline measurements. 

Corlux was well tolerated and enabled almost 50% of patients taking anti-diabetic, insulin and hypertensive medications at enrollment to reduce the dosage by study’s end.

Release Date: June 4, 2011
Source: Corcept Therapeutics Incorporated 


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE